Memantine Hydrochloride Tablet, Film Coated
Product Images NDC 50090-4434

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Memantine Hydrochloride (NDC 50090-4434). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by A-s Medication Solutions, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 01

Chemical structure diagram of memantine hydrochloride showing the arrangement of the adamantane framework with amine and methyl substitutions, consistent with the active ingredient memantine hydrochloride.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 02

A line graph comparing mean changes from baseline in ADCS-ADL scores over 28 weeks of treatment for Memantine Hydrochloride and placebo groups. The y-axis ranges from clinical decline to clinical improvement, while the x-axis shows weeks of treatment (0, 4, 12, 28). Memantine Hydrochloride group shows less decline over time compared to placebo, with error bars for SEM included.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 03

A line graph comparing the cumulative percentage of patients over change from baseline in ADCS-ADL scores between Memantine Hydrochloride and placebo groups. The x-axis represents ADCS-ADL change from baseline, and the y-axis indicates cumulative percentage of patients. Memantine Hydrochloride curve is marked with open circles, placebo with solid squares.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 04

A line graph depicting mean change from baseline in SIB score over weeks of treatment comparing memantine hydrochloride and placebo groups. The y-axis shows change from baseline with labels for clinical improvement and decline, while the x-axis shows treatment duration in weeks up to 28. The graph includes error bars for standard error of the mean (SEM).*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 05

A line graph showing the cumulative percentage of patients on the vertical axis versus SIB (Severe Impairment Battery) change from baseline on the horizontal axis. The graph compares two groups: one treated with Memantine Hydrochloride and the other with placebo. The Memantine Hydrochloride group shows a higher cumulative percentage of patients across the range of SIB change values compared to placebo.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 06

A line graph depicting mean change from baseline in ADAS-cog scores over 24 weeks of treatment. Two groups are shown: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The graph includes error bars and indicates clinical improvement and decline thresholds on the vertical axis.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 07

A cumulative percentage of patients graph showing ADCS-ADL change from baseline on the x-axis and cumulative percentage on the y-axis. The graph compares two groups: Placebo/Donepezil and Memantine Hydrochloride/Donepezil, with data points represented by squares and circles respectively, illustrating patient response differences over the measured range.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 08

A line graph comparing mean change from baseline in SIB score over 24 weeks of treatment between Placebo/Donepezil and Memantine Hydrochloride/Donepezil groups. The vertical axis shows change with labels for clinical improvement and decline, and the horizontal axis represents weeks of treatment. Data points with error bars illustrate trends for both groups over time.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 09

A line graph showing the cumulative percentage of patients versus SIB change from baseline comparing two treatments: Placebo/Donepezil and Memantine Hydrochloride/Donepezil. The plot illustrates patient response over a range of SIB score changes with markers distinguishing the two treatments.*

FDA Label Image

16cd3370 8ddc 4dbb 82b3 98e128fb3482 10

FDA Label Image

Label Image (Lbl500904434)

Memantine Hydrochloride 10 mg film-coated tablets label from A-S Medication Solutions. The label indicates oral use, with 90 tablets per package. Storage instructions specify keeping the product at 68 to 77 degrees Fahrenheit. The label includes the product NDC 50090-4434 and batch/lot information.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.